EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score

Giulia Mazzaschi, Alessandro Lazzarin, Matteo Santoni, Francesca Trentini, Ugo De Giorgi, Nicole Brighi, Chiara Tommasi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher, Alessia Mennitto, Carlo Cattrini und 13 weitere

Frontiers in Bioscience-Elite · 2023

DOI: 10.31083/j.fbe1503020 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Frontiers in Bioscience-Elite, 2023. Verfasst von Giulia Mazzaschi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The advent of immune checkpoint inhibitors (ICIs) has revolutionized the metastatic renal cell carcinoma (mRCC) therapeutic landscape. Nevertheless, tyrosine-kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF) axis still play a key role. The aim of the present study was to explore the prognostic performance of an integrated blood score, based on hemoglobin (Hb) concentration, mean corpuscular volume (MCV), and red cell distribution width (RDW), in mRCC patients treated with anti-VEGF TKIs. The primary endpoint was to correlate Hb, MCV, and RDW with progression-free survival (PFS) and overall survival (OS). Materials and Methods: Our multicenter retrospective observational study involved mRCC patients treated with pazopanib or cabozantinib from January 2012 to December 2020 in nine Italian centers. Clinical records and laboratory data, including Hb levels, MCV, and RDW, were collected at baseline. Descriptive statistics and univariate and multivariate analyses were performed.

Results

We enrolled 301 mRCC patients of which 179 (59%) underwent pazopanib, and 122 (41%) cabozantinib. We considered baseline Hb ≥12 g/dL, MCV >87 fL, and RDW ≤16% as good prognostic factors; hence, developing a multiparametric score capable of delineating 4 different categories. The number of good prognostic factors was associated with significantly longer PFS and OS (p < 0.001 for both). Therefore, we developed a red blood cell-based score by stratifying cases into two groups (2–3 versus 0–1, good factors). The impact on PFS and OS was even more striking (median PFS (mPFS): 16.3 vs 7.9 months; median OS (mOS): 33.7 vs 14.1 months)), regardless of the TKI agent. When challenged with univariate and multivariate analysis, the blood score maintained its high prognostic significance in terms of OS (multivariate analysis HR for OS: 0.53, 95% CI 0.39–0.75; p < 0.001, respectively), while the impact on PFS resulted in borderline significance.

Conclusions

Our analyses demonstrate the prognostic role of a multiparametric score based on easily exploitable blood parameters, such as Hb concentration, MCV, and RDW. The red blood cell-based score may underlie the upregulation of the HIF-1α pathway and VEGF axis, thereby identifying a selected population who is likely to benefit from TKI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansVascular Endothelial Growth Factor APrognosisErythrocytesHemoglobinsAnilidesPyridinesIndazolesPyrimidinesSulfonamides

Stichwörter der Autor:innen

HIFHbMCVRDWanemiaanisocytosismacrocytosismetastatic renal cell carcinoma (mRCC)prognostic scoretyrosine-kinase inhibitors

Substanzen

Vascular Endothelial Growth Factor AHemoglobinscabozantinibAnilidesPyridinespazopanibIndazolesPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
  • Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy.
  • Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), 43126 Parma, Italy.
  • Oncology Unit, Macerata Hospital, 62100 Macerata, Italy.
  • Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori'', 47014 Meldola, Italy.
  • Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16122 Genova, Italy.

Zitieren

APA

Mazzaschi, G., Lazzarin, A., Santoni, M., Trentini, F., Giorgi, U., Brighi, N., Tommasi, C., Puglisi, S., Caffo, O., Kinspergher, S., Mennitto, A., Cattrini, C., Verzoni, E., Rametta, A., Stellato, M., Malgeri, A., Roviello, G., Silini, E. M., Rescigno, P., …, & Buti, S. (2023). Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score. Frontiers in Bioscience-Elite. https://doi.org/10.31083/j.fbe1503020

Vancouver

Mazzaschi G, Lazzarin A, Santoni M, Trentini F, Giorgi U, Brighi N, et al. Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score. Frontiers in Bioscience-Elite. 2023. doi:10.31083/j.fbe1503020

BibTeX
@article{Mazzaschi2023,
  author = {Mazzaschi, Giulia and Lazzarin, Alessandro and Santoni, Matteo and Trentini, Francesca and Giorgi, Ugo De and Brighi, Nicole and Tommasi, Chiara and Puglisi, Silvia and Caffo, Orazio and Kinspergher, Stefania and Mennitto, Alessia and Cattrini, Carlo and Verzoni, Elena and Rametta, Alessandro and Stellato, Marco and Malgeri, Andrea and Roviello, Giandomenico and Silini, Enrico Maria and Rescigno, Pasquale and Rebuzzi, Sara Elena and Fornarini, Giuseppe and Quaini, Federico and Giudice, Giulia Claire and Banna, Giuseppe Luigi and Buti, Sebastiano},
  title = {Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score},
  journal = {Frontiers in Bioscience-Elite},
  year = {2023},
  doi = {10.31083/j.fbe1503020}
}
Kostenlos starten →